Cargando…
Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
The prognosis of patients with advanced gastric cancer (GC) remains poor despite the recent advances in molecular targeted therapies, and the search for biomarkers that can predict prognosis and additional new agents with acceptable toxicity profiles are needed. Lipolysis-stimulated lipoprotein rece...
Autores principales: | Sugase, Takahito, Takahashi, Tsuyoshi, Serada, Satoshi, Fujimoto, Minoru, Ohkawara, Tomoharu, Hiramatsu, Kosuke, Koh, Masahiro, Saito, Yurina, Tanaka, Koji, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Yamasaki, Makoto, Nakajima, Kiyokazu, Hanazaki, Kazuhiro, Mori, Masaki, Doki, Yuichiro, Naka, Tetsuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152476/ https://www.ncbi.nlm.nih.gov/pubmed/30250639 http://dx.doi.org/10.18632/oncotarget.25952 |
Ejemplares similares
-
Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
por: Sugase, Takahito, et al.
Publicado: (2021) -
Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
por: Nishigaki, Takahiko, et al.
Publicado: (2020) -
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019) -
Overexpression of leucine‐rich α2‐glycoprotein‐1 is a prognostic marker and enhances tumor migration in gastric cancer
por: Yamamoto, Masaaki, et al.
Publicado: (2017) -
Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
por: Hara, Hisashi, et al.
Publicado: (2016)